Cediranib maleate is under clinical development by AstraZeneca and currently in the Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Cediranib maleate’s likelihood of approval (LoA) and phase transition for Epithelial Ovarian Cancer took place on 09 Mar 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Cediranib maleate Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Cediranib maleate overview

Cediranib (AZD2171, Recentin) is under development for the treatment of cervical cancer, platinum-sensitive relapsed epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer. The drug candidate is administered orally as a coated tablet. It targets all three vascular endothelial growth factor receptor (VEGFR-1,-2,-3) tyrosine kinases.

It was also under development for the treatment of endometrial cancer, colorectal cancer, glioblastoma multiforme (GBM), gastrointestinal stromal tumors (GIST), renal cell carcinoma, solid tumors, non-small cell lung cancer, liver diseases, acute myelocytic leukemia (AML), head and neck cancer, alveolar soft part sarcoma, thyroid cancer and prostate cancer, breast cancer, malignant pleural mesothelioma.

AstraZeneca overview

AstraZeneca is a biopharmaceutical company, which is focused on discovery, production and commercialization of a range of prescription drugs. It develops products related to therapy areas such as respiratory, cardiovascular, renal and metabolic diseases, cancer, autoimmune, infection and neurological diseases. The company’s product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly-owned local marketing companies, distributors and local representative offices. The company markets its products to primary care and specialty care physicians. The COVID-19 Vaccine AstraZeneca has been approved for conditional marketing or emergency use. The company operates in Europe, the Americas, Asia, Africa and Australasia. AstraZeneca is headquartered in Cambridge, Cambridgeshire, the UK.

Quick View Cediranib maleate LOA Data

Report Segments
  • Innovator
Drug Name
  • Cediranib maleate
Administration Pathway
  • Oral
Therapeutic Areas
  • Gastrointestinal
  • Oncology
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.